BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients

被引：31

作者：

Gilli, Stefanie ^{[1
]}

Novak, Urban ^{[1
]}

Taleghani, Behrouz Mansouri ^{[2
]}

Baerlocher, Gabriela M. ^{[2
]}

Leibundgut, Kurt ^{[3
]}

Banz, Yara ^{[4
]}

Zander, Thilo ^{[5
]}

Betticher, Daniel ^{[6
]}

Egger, Thomas ^{[7
]}

Rauch, Daniel ^{[8
]}

Pabst, Thomas ^{[1
]}

机构：

[1] Univ Hosp Bern, Dept Med Oncol, CH-3010 Bern, Switzerland

[2] Univ Hosp Bern, Dept Hematol, Bern, Switzerland

[3] Univ Hosp Bern, Dept Pediat Hematooncol, Inselspital, Bern, Switzerland

[4] Univ Bern, Inst Pathol, Bern, Switzerland

[5] Kantonsspital, Dept Oncol, Luzern, Switzerland

[6] Kantonsspital, Dept Oncol, Fribourg, Switzerland

[7] Kantonsspital, Dept Oncol, Solothurn, Switzerland

[8] Regionalspital, Dept Oncol, Thun, Switzerland

来源：

ANNALS OF HEMATOLOGY | 2017年 / 96卷 / 03期

关键词：

Autologous; Stem cell; Transplantation; Bendamustine; Lymphoma; Beam; BeEAM; BCNU; Prognosis; Survival; High dose; Chemotherapy; STEM-CELL TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; HIGH-DOSE CHEMOTHERAPY; BONE-MARROW-TRANSPLANTATION; MULTICENTER PHASE-II; B-CELL; MANTLE CELL; PLUS RITUXIMAB; CONVENTIONAL CHEMOTHERAPY; INTENSIFIED CHEMOTHERAPY;

D O I：

10.1007/s00277-016-2900-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BEAM with BCNU is commonly used for conditioning treatment followed by autologous stem cell transplantation (ASCT). However, pulmonary toxicity and availability issues associated with BCNU prompted us to evaluate bendamustine-replacing BCNU (BeEAM). We analyzed 39 lymphoma patients receiving BeEAM conditioning with 200 mg/m(2) bendamustine at days -7 and -6. The median duration until neutrophil recovery was 11 days, and 15 days for platelet recovery (> 20 g/L). The most common grade 3/4 non-hematologic toxicities comprised mucosal side effects (27 pts.). Pulmonary toxicity was observed in one patient (2.5%), and one patient died of septic complications. The CR rate increased from 33% to 74% 100 days after ASCT. After a median follow-up of 18.5 months, progression and death each occurred in 11 patients (28%). Median progression-free and overall survival at 2 years were 69% and 72%. Our data suggest that BeEAM conditioning using bendamustine is safe and results in promising survival rates.

引用

页码：421 / 429

页数：9

共 37 条

[31] Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support:: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) [J].

Tarella, C. ;

Zanni, M. ;

Di Nicola, M. ;

Patti, C. ;

Calvi, R. ;

Pescarollo, A. ;

Zoli, V. ;

Fornari, A. ;

Novero, D. ;

Cabras, A. ;

Stella, M. ;

Comino, A. ;

Remotti, D. ;

Ponzoni, M. ;

Caracciolo, D. ;

Ladetto, M. ;

Magni, M. ;

Devizzi, L. ;

Rosato, R. ;

Boccadoro, M. ;

Bregni, M. ;

Corradini, P. ;

Gallamini, A. ;

Majolino, I. ;

Mirto, S. ;

Gianni, A. M. .

LEUKEMIA, 2007, 21 (08) :1802-1811

[32] BCNU-associated pneumonitis: portrait of a toxicity [J].

Till, Brian G. ;

Madtes, David K. .

LEUKEMIA & LYMPHOMA, 2012, 53 (06) :1019-1020

[33] Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma [J].

Visani, Giuseppe ;

Stefani, Pietro Maria ;

Capria, Saveria ;

Malerba, Lara ;

Galieni, Piero ;

Gaudio, Francesco ;

Specchia, Giorgina ;

Meloni, Giovanna ;

Gherlinzoni, Filippo ;

Gonella, Roberta ;

Gobbi, Marco ;

Santoro, Armando ;

Ferrara, Felicetto ;

Rocchi, Marco ;

Ocio, Enrique M. ;

Dolores Caballero, Maria ;

Loscocco, Federica ;

Isidori, Alessandro .

BLOOD, 2014, 124 (19) :3029-3031

[34] BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients [J].

Visani, Giuseppe ;

Malerba, Lara ;

Stefani, Pietro Maria ;

Capria, Saveria ;

Galieni, Piero ;

Gaudio, Francesco ;

Specchia, Giorgina ;

Meloni, Giovanna ;

Gherlinzoni, Filippo ;

Giardini, Claudio ;

Falcioni, Sadia ;

Cuberli, Francesca ;

Gobbi, Marco ;

Sarina, Barbara ;

Santoro, Armando ;

Ferrara, Felicetto ;

Rocchi, Marco ;

Ocio, Enrique M. ;

Dolores Caballero, Maria ;

Isidori, Alessandro .

BLOOD, 2011, 118 (12) :3419-3425

[35] Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma [J].

Vose, JM ;

Bierman, PJ ;

Enke, C ;

Hankins, J ;

Bociek, G ;

Lynch, JC ;

Armitage, JO .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) :461-467

[36] Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma [J].

Vose, Julie M. ;

Bierman, Philip J. ;

Loberiza, Fausto R. ;

Enke, Charles ;

Hankins, Jordan ;

Bociek, Robert G. ;

Chan, Wing C. ;

Weisenburger, Dennis D. ;

Armitage, James O. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (01) :123-128

[37] Phase I/II Study of Bortezomib-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin Lymphoma, Transformed, or Mantle Cell Lymphoma [J].

William, Basem M. ;

Allen, Mary S. ;

Loberiza, Fausto R., Jr. ;

Bociek, Robert Gregory ;

Bierman, Philip J. ;

Armitage, James O. ;

Vose, Julie M. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (04) :536-542

← 1 2 3 4 →